Baird analyst David Rescott raised the firm’s price target on Edwards Lifesciences (EW) to $87 from $85 and keeps a Neutral rating on the shares. The firm updated its model following beat and raise Q1 results on elevated expectationsbut valuation seems stretched.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $100 from $103 at BofA
- Closing Bell Movers: Intel jumps 19% on blowout earnings
- Edwards Lifesciences sees Q2 EPS 70c-76c, consensus 75c
- Edwards Lifesciences reports Q1 EPS 78c, consensus 73c
- Edwards Lifesciences raises FY26 EPS view to $2.95-$3.05 from $2.90-$3.05